TY - JOUR
T1 - Central diabetes insipidus in refractory antineutrophil cytoplasmic antibody-associated vasculitis
AU - Ohashi, Keiji
AU - Morishita, Michiko
AU - Watanabe, Haruki
AU - Sada, Kenei
AU - Katsuyama, Takayuki
AU - Miyawaki, Yoshia
AU - Katsuyama, Eri
AU - Narazaki, Mariko
AU - Tatebe, Noriko
AU - Watanabe, Katsue
AU - Kawabata, Tomoko
AU - Wada, Jun
N1 - Funding Information:
This work was supported by the Research Committee of Intractable Vasculitis Syndrome of the Ministry of Health, Labour, and Welfare of Japan under Grant <nannti-ippann-044>.
Publisher Copyright:
© 2017 The Japanese Society of Internal Medicine.
PY - 2017
Y1 - 2017
N2 - We herein describe two cases of refractory antineutrophil cytoplasmic antibody-associated vasculitis (AAV) complicated with diabetes insipidus (DI) possibly related to hypertrophic pachymeningitis (HP). One patient had microscopic polyangiitis and HP, which were refractory to cyclophosphamide, azathioprine, rituximab, mycophenolate mofetil (MMF), and mizoribine. Remission was finally achieved with the use of etanercept, but DI occurred 5 years later. The other patient had granulomatosis with polyangiitis, which that was refractory to cyclophosphamide, methotrexate, MMF, and rituximab. DI subsequently developed, but was successfully treated with etanercept. Dura mater hypertrophy was macroscopically observed in the latter case.
AB - We herein describe two cases of refractory antineutrophil cytoplasmic antibody-associated vasculitis (AAV) complicated with diabetes insipidus (DI) possibly related to hypertrophic pachymeningitis (HP). One patient had microscopic polyangiitis and HP, which were refractory to cyclophosphamide, azathioprine, rituximab, mycophenolate mofetil (MMF), and mizoribine. Remission was finally achieved with the use of etanercept, but DI occurred 5 years later. The other patient had granulomatosis with polyangiitis, which that was refractory to cyclophosphamide, methotrexate, MMF, and rituximab. DI subsequently developed, but was successfully treated with etanercept. Dura mater hypertrophy was macroscopically observed in the latter case.
KW - Antineutrophil cytoplasmic antibody-associated vasculitis
KW - Diabetes insipidus
KW - Etanercept
KW - Hypertrophic pachymeningitis
KW - Rituximab
UR - http://www.scopus.com/inward/record.url?scp=85032731778&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032731778&partnerID=8YFLogxK
U2 - 10.2169/internalmedicine.8683-16
DO - 10.2169/internalmedicine.8683-16
M3 - Article
C2 - 28943556
AN - SCOPUS:85032731778
VL - 56
SP - 2943
EP - 2948
JO - Internal Medicine
JF - Internal Medicine
SN - 0918-2918
IS - 21
ER -
